$NVS

Ionis (IONS) and Milestone (MIST) gained FDA approvals for neurology and cardiology drugs. Biogen (BIIB) and AstraZeneca (AZN) also received regulatory nods for Alzheimer's and cancer treatments. Novavax (NVAX) secured global approvals for its COVID-19 vaccine. TScan (TCRX) and Novartis (NVS) announced job cuts. Novartis (NVS) and HUTCHMED (HCM) struck deals worth up to $3.2B and $1.295B respectively.

Novartis has secured exclusive rights to develop and commercialize subcutaneous versions of several products using Alteogen’s ALT-B4 technology. The deal could be worth up to $3.223 billion plus royalties if all options and milestones are met. This technology could potentially be used across multiple products, helping Novartis prepare for patent losses on major medicines. Alteogen has also signed similar deals with Biogen and GSK’s Tesaro. Novartis is also investing in other delivery technologie

Novartis halted eight clinical trials of its experimental cell therapy rap-cel after three patients died from severe immune reactions. The pause affects trials for autoimmune and neurological disorders. Novartis is reviewing the deaths and sharing information with health authorities. Bristol Myers also paused studies of its rival CAR T-cell treatment zola-cel. Novartis shares rose 4% on Tuesday.

Novartis agreed to a $3.22bn deal with Alteogen for ALT-B4, a subcutaneous drug delivery technology. The agreement includes option fees, milestones, and royalties. Novartis gains global rights to develop subcutaneous versions of its biologic products, expanding its portfolio in a competitive market.

Novartis reported that remibrutinib, an oral BTK inhibitor, significantly reduced relapse rates compared to teriflunomide in two Phase 3 trials for relapsing multiple sclerosis, with no liver safety signals. Full data, including relapse rates and adverse events, will be presented in October 2026. The drug is not yet approved for MS.

Novartis (NVS) plans to relocate labs and end small-scale biologics production at its Kleinbasel site, potentially cutting 130 jobs. The move aims to consolidate operations at its main Basel campus by 2028, with production shifting to other European facilities. The company cites lease expirations and strategic optimization, not weak demand, as reasons. Novartis also reported positive late-stage results for remibrutinib, a potential growth driver. Investors may focus on execution risks and long-t

Novartis (NYSE: NVS) has agreed to pay up to $3 billion for licensing options to Alteogen's Hybrozyme drug-delivery platform, which enhances the absorption of biologics. The deal includes option fees, milestones, and royalties, with Novartis aiming to convert IV infusions into subcutaneous injections. Novartis shares are at $162.46, with a market cap of $308.79 billion. The company sees this as a way to defend against biosimilars and improve patient convenience.

Novartis reported positive phase 3 trial results for remibrutinib, showing superiority over teriflunomide in reducing relapse rates and brain lesions in relapsing multiple sclerosis. The drug demonstrated safety and efficacy in key endpoints. Novartis aims to address unmet needs in oral therapies for RMS. (NVS)

Novartis halted eight trials of rapcabtagene autoleucel in autoimmune diseases after three patient deaths. The pause, effective Aug. 24, affects trials for lupus, rheumatoid arthritis, and other conditions. Bristol Myers Squibb also paused its zolacabtagene autoleucel trials as a precaution. Both companies are reviewing the incidents. Two lymphoma and leukemia trials of rapcabtagene autoleucel were not impacted.

Novartis has licensed Alteogen's ALT-B4 drug delivery tech for up to $3.2bn. The tech allows subcutaneous delivery of drugs normally given intravenously. Alteogen's CEO highlights the platform's commercial value. GSK and AstraZeneca have also licensed the tech for up to $265m and $1.35bn, respectively.